Compare ATCH & PDSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ATCH | PDSB |
|---|---|---|
| Founded | 2022 | 2005 |
| Country | United States | United States |
| Employees | N/A | 10 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.9M | 29.6M |
| IPO Year | 2024 | 2015 |
| Metric | ATCH | PDSB |
|---|---|---|
| Price | $0.20 | $0.59 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | ★ 1.4M | 413.5K |
| Earning Date | 05-15-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.16 |
| EPS | ★ 0.06 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.36 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.14 | $0.51 |
| 52 Week High | $1.92 | $1.90 |
| Indicator | ATCH | PDSB |
|---|---|---|
| Relative Strength Index (RSI) | 45.08 | 45.48 |
| Support Level | $0.18 | $0.52 |
| Resistance Level | $0.21 | $1.16 |
| Average True Range (ATR) | 0.01 | 0.07 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 70.38 | 41.10 |
AtlasClear Holdings Inc is a fintech company. Its goal is to build a cutting-edge technology-enabled financial services firm that would create a more efficient platform for trading, clearing, settlement, and banking of evolving and financial products with a focus on financial services firms. It is a fintech-driven business-to-business platform that expects to power innovation in fintech, investing, and trading. The company believes it is positioned to provide a modern, mission-critical suite of solutions to its clients, enabling them to reduce their transaction costs and compete more effectively in their businesses.
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.